Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)

Size: px
Start display at page:

Download "Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)"

Transcription

1 Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract Type Contract Number Jurisdiction State(s) Palmetto GBA A and B MAC MAC A J - J Alabama Palmetto GBA A and B MAC MAC A J - J Georgia Palmetto GBA A and B MAC MAC A J - J Tennessee Palmetto GBA A and B and HHH MAC MAC A J - M South Carolina Palmetto GBA A and B and HHH MAC MAC B J - M South Carolina Palmetto GBA A and B and HHH MAC MAC A J - M Virginia Palmetto GBA A and B and HHH MAC MAC B J - M Virginia Palmetto GBA A and B and HHH MAC MAC A J - M West Virginia Palmetto GBA A and B and HHH MAC MAC B J - M West Virginia Palmetto GBA A and B and HHH MAC MAC A J - M North Carolina Palmetto GBA A and B and HHH MAC MAC B J - M North Carolina Back to Top LCD Information Document Information LCD ID L34426 Original ICD-9 LCD ID L31557 LCD Title Ophthalmic Angiography (Fluorescein and Indocyanine Green) Proposed LCD in Comment Period N/A Source Proposed LCD N/A AMA CPT / ADA CDT / AHA NUBC Copyright Statement Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 01/29/2018 Revision Ending Date 02/25/2018 Retirement Date N/A Notice Period Start Date 09/08/2016 Notice Period End Date 10/23/2016 Printed on 1/29/2018. Page 1 of 24

2 CPT only copyright American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association. UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ( AHA ), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA. Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company. CMS National Coverage Policy Title XVIII of the Social Security Act, 1862 (a)(1)(a) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. Title XVIII of the Social Security Act, 1862 (a)(14) defines other than physician services. Title XVIII of the Social Security Act, 1862 (a)(7) excludes routine physical examinations. Title XVIII of the Social Security Act, 1833 (e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim. 42 CFR (a) indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements). 42 CFR defines physician assistants' services. 42 CFR defines nurse practitioners' services. 42 CFR defines clinical nurse specialists' services. CMS Internet-Only Manual, Pub , Medicare National Coverage Determinations Manual, Chapter 1, Part 1, 80.2, , 80.3 & Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: Fluorescein Fluorescein angiography is used in the diagnosis and treatment of a wide range of ocular disorders. Its visible fluorescence leaking from damaged vessels makes it particularly useful in the diagnosis of retinal vascular disorders and monitoring treatment of conditions amenable to laser photocoagulation. Printed on 1/29/2018. Page 2 of 24

3 The dye is injected intravenously and serial photographs are taken through the pupil. While morphological characteristics alone may be pathognomonic of certain disease states, the timing of appearance of the dye in the choroid, in the central retinal artery and in the filling (or otherwise) of the quadrants have diagnostic implications. Indocyanine Green Indocyanine green dye is injected intravenously into the patient to highlight the vessels in the retina and the deeper tissue layer of the choroid. Under infrared light, Indocyanine Green fluoresces allowing the choroidal vessels to be visualized through the retinal pigment epithelium or in the presence of retinal or vitreous hemorrhage that would otherwise obscure visualization. Indocyanine green angiography (ICG) is effective in the diagnosis and treatment of ill-defined choroidal neovascularization (e.g., associated with age related macular degeneration (AMD)). It is also useful in the evalution of feeder vessels, choroidal leakages in the late phase, and ruptures of the pigment epithelium. Indications: Fluorescein Fluorescein angiography with interpretation is medically necessary as an adjunct to the diagnosis of chorioretinal vascular abnormalities especially relating to choroid neovascularization, noninfective vasculitis, and age related macular degeneration. It may also be appropriate in evaluating intraocular tumors, visual loss in systemic disease, acute exudative inflammations such as toxoplasmosis and optic disc edema. Medical necessity for such angiography would generally be in the context of a changing clinical picture. Fluorescein angiography may be useful in diabetic retinopathy in identifying ischemia and neovascularization, locating microaneurysms, and defining macular edema. Fluorescein angiography following treatment, for example, of choroidal neovascularization (CNV) is necessary to monitor for recurrence or to detect additional treatable disease. Usually this is performed on the basis of a change in the clinical picture similar to the way it is employed prior to treatment. However, fluorescein angiography may be performed following treatment without clinical change in order to detect occult lesions. This will occur most often in CNV and very rarely in other diseases. Indocyanine Green Indocyanine green angiography (ICG) may be a valuable diagnostic adjunct to fluorescein angiography in the evaluation of the following conditions: Retinal neovascularization Choroid neovascularization Serous detachment of retinal pigment epithelium Hemorrhagic detachment of retinal pigment epithelium Retinal hemorrhage Limitations: Fluorescein Studies performed for screening will be denied by Medicare as not medically necessary. Fluorescein angiography must be performed under the direct supervision (physician present in the office and immediately available) of a physician when done by a non-physician practitioner. If excluded by State law, optometrists may not be reimbursed for fluorescein angiography. Fluorescein angiography of an asymptomatic contralateral without new abnormalities on ophthalmoscopic exam, in patients with unilateral AMD or other disease, will be denied as not medically necessary. Evidence of medical necessity must be documented in the medical record for each. Indocyanine Green Indocyanine green angiography must be performed under the direct supervision (physician present in the office and immediately available) of a physician when done by a non-physician practitioner. Printed on 1/29/2018. Page 3 of 24

4 If excluded by State law, optometrists may not be reimbursed for ICG angiography. Indocyanine green is formulated with iodine and should not be used on patients who are allergic to iodine. ICG for the evaluation of patients with background diabetic retinopathy is not considered to be a medically necessary service. ICG angiography of an asymptomatic contralateral without new abnormalities on ophthalmoscopic exam, in patients with unilateral AMD or other disease, will be denied as not medically necessary. Evidence of medical necessity must be documented in the medical record for each. Studies performed for screening will be denied by Medicare as not medically necessary. Other Comments: Limitation of liability and refund requirements apply when denials are based on medical necessity. The provider/supplier must notify the beneficiary in writing, prior to rendering the service, if the provider/supplier is aware that the test, item or procedure may not be considered medically necessary by Medicare. The limitation of liability and refund requirements do not apply when the test, item or procedure is statutorily excluded, has no Medicare benefit category or is rendered for screening purposes. For outpatient settings other than CORFs, references to "physicians" throughout this policy include nonphysicians, such as nurse practitioners, clinical nurse specialists and physician assistants. Such non-physician practitioners, with certain exceptions, may certify, order and establish the plan of care as authorized by State law. (See Section CMS National Coverage Policy). Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A Back to Top Coding Information Bill Type Codes: Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims. N/A Revenue Codes: Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes. Printed on 1/29/2018. Page 4 of 24

5 N/A CPT/HCPCS Codes Group 1 Paragraph: CPT Code can only be billed with a single diagnosis if that diagnosis is a covered diagnosis for both CPT Code and CPT Code If the diagnosis to be billed for CPT is only a covered diagnosis for one of the two procedures encompassed in CPT 92242, the provider also needs to include a second diagnosis code on the claim that is a covered diagnosis for the other of the two studies in order to indicate that there exists a covered diagnosis for both studies included in CPT Group 1 Codes: FLUORESCEIN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) WITH INTERPRETATION AND REPORT, UNILATERAL OR BILATERAL INDOCYANINE-GREEN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) WITH INTERPRETATION AND REPORT, UNILATERAL OR BILATERAL FLUORESCEIN ANGIOGRAPHY AND INDOCYANINE-GREEN ANGIOGRAPHY (INCLUDES MULTIFRAME IMAGING) PERFORMED AT THE SAME PATIENT ENCOUNTER WITH INTERPRETATION AND REPORT, UNILATERAL OR BILATERAL ICD-10 Codes that Support Medical Necessity Group 1 Paragraph: The correct use of an ICD-10 code listed below does not assure coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this determination. ICD-10 Codes for Fluorescein Angiography (92235) Group 1 Codes: ICD-10 Codes A18.53 Tuberculous chorioretinitis B20 Human immunodeficiency virus [HIV] disease B39.4 Histoplasmosis capsulati, unspecified B39.5 Histoplasmosis duboisii B39.9 Histoplasmosis, unspecified B58.01 Toxoplasma chorioretinitis C69.20 Malignant neoplasm of unspecified retina C69.21 Malignant neoplasm of right retina C69.22 Malignant neoplasm of left retina C69.30 Malignant neoplasm of unspecified choroid C69.31 Malignant neoplasm of right choroid C69.32 Malignant neoplasm of left choroid D18.09 Hemangioma of other sites D31.20 Benign neoplasm of unspecified retina D31.21 Benign neoplasm of right retina D31.22 Benign neoplasm of left retina D31.30 Benign neoplasm of unspecified choroid D31.31 Benign neoplasm of right choroid D31.32 Benign neoplasm of left choroid D57.00 Hb-SS disease with crisis, unspecified D57.01 Hb-SS disease with acute chest syndrome D57.02 Hb-SS disease with splenic sequestration D57.1 Sickle-cell disease without crisis D57.20 Sickle-cell/Hb-C disease without crisis D Sickle-cell/Hb-C disease with acute chest syndrome D Sickle-cell/Hb-C disease with splenic sequestration D Sickle-cell/Hb-C disease with crisis, unspecified D57.80 Other sickle-cell disorders without crisis Printed on 1/29/2018. Page 5 of 24

6 ICD-10 Codes D Other sickle-cell disorders with acute chest syndrome D Other sickle-cell disorders with splenic sequestration D Other sickle-cell disorders with crisis, unspecified D86.0 Sarcoidosis of lung D86.1 Sarcoidosis of lymph nodes D86.2 Sarcoidosis of lung with sarcoidosis of lymph nodes D86.3 Sarcoidosis of skin D86.81 Sarcoid meningitis D86.82 Multiple cranial nerve palsies in sarcoidosis D86.83 Sarcoid iridocyclitis D86.84 Sarcoid pyelonephritis D86.85 Sarcoid myocarditis D86.86 Sarcoid arthropathy D86.87 Sarcoid myositis D86.89 Sarcoidosis of other sites D86.9 Sarcoidosis, unspecified E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right Printed on 1/29/2018. Page 6 of 24

7 ICD-10 Codes E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left E Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left E Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, E08.36 Diabetes mellitus due to underlying condition with diabetic cataract E08.37X1 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right E08.37X2 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left E08.37X3 Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, E08.39 Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right Printed on 1/29/2018. Page 7 of 24

8 ICD-10 Codes E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left E Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, E09.36 Drug or chemical induced diabetes mellitus with diabetic cataract E09.37X1 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right E09.37X2 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left E09.37X3 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, E09.39 Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Printed on 1/29/2018. Page 8 of 24

9 ICD-10 Codes Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left E Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, E Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified E10.37X1 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right E10.37X2 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left E10.37X3 Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, E10.39 Type 1 diabetes mellitus with other diabetic ophthalmic complication E Printed on 1/29/2018. Page 9 of 24

10 ICD-10 Codes Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left E Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left Printed on 1/29/2018. Page 10 of 24

11 ICD-10 Codes E Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, E11.36 Type 2 diabetes mellitus with diabetic cataract E11.37X1 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right E11.37X2 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left E11.37X3 Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, E11.39 Type 2 diabetes mellitus with other diabetic ophthalmic complication E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right Printed on 1/29/2018. Page 11 of 24

12 ICD-10 Codes E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left E Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left E Other specified diabetes mellitus with stable proliferative diabetic retinopathy, E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left E Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, E13.36 Other specified diabetes mellitus with diabetic cataract E13.37X1 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right E13.37X2 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left E13.37X3 Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, E13.39 Other specified diabetes mellitus with other diabetic ophthalmic complication E78.00 Pure hypercholesterolemia, unspecified E78.01 Familial hypercholesterolemia E Postprocedural hematoma of an endocrine system organ or structure following an endocrine system procedure E Postprocedural hematoma of an endocrine system organ or structure following other procedure E Postprocedural seroma of an endocrine system organ or structure following an endocrine system procedure E Postprocedural seroma of an endocrine system organ or structure following other procedure G35 Multiple sclerosis G45.3 Amaurosis fugax G93.2 Benign intracranial hypertension H Unspecified focal chorioretinal inflammation, right H Unspecified focal chorioretinal inflammation, left H Unspecified focal chorioretinal inflammation, H Focal chorioretinal inflammation, juxtapapillary, right H Focal chorioretinal inflammation, juxtapapillary, left H Focal chorioretinal inflammation, juxtapapillary, H Focal chorioretinal inflammation of posterior pole, right H Focal chorioretinal inflammation of posterior pole, left H Focal chorioretinal inflammation of posterior pole, H Focal chorioretinal inflammation, peripheral, right H Focal chorioretinal inflammation, peripheral, left H Focal chorioretinal inflammation, peripheral, H Focal chorioretinal inflammation, macular or paramacular, right H Focal chorioretinal inflammation, macular or paramacular, left H Focal chorioretinal inflammation, macular or paramacular, H Unspecified disseminated chorioretinal inflammation, right H Unspecified disseminated chorioretinal inflammation, left H Unspecified disseminated chorioretinal inflammation, H Disseminated chorioretinal inflammation of posterior pole, right H Disseminated chorioretinal inflammation of posterior pole, left H Disseminated chorioretinal inflammation of posterior pole, H Disseminated chorioretinal inflammation, peripheral right H Disseminated chorioretinal inflammation, peripheral, left H Disseminated chorioretinal inflammation, peripheral, H Disseminated chorioretinal inflammation, generalized, right H Disseminated chorioretinal inflammation, generalized, left H Disseminated chorioretinal inflammation, generalized, Printed on 1/29/2018. Page 12 of 24

13 ICD-10 Codes H Acute posterior multifocal placoid pigment epitheliopathy, right H Acute posterior multifocal placoid pigment epitheliopathy, left H Acute posterior multifocal placoid pigment epitheliopathy, H30.21 Posterior cyclitis, right H30.22 Posterior cyclitis, left H30.23 Posterior cyclitis, H Harada's disease, right H Harada's disease, left H Harada's disease, H Other chorioretinal inflammations, right H Other chorioretinal inflammations, left H Other chorioretinal inflammations, H30.91 Unspecified chorioretinal inflammation, right H30.92 Unspecified chorioretinal inflammation, left H30.93 Unspecified chorioretinal inflammation, H Solar retinopathy, right H Solar retinopathy, left H Solar retinopathy, H Choroidal degeneration, unspecified, right H Choroidal degeneration, unspecified, left H Choroidal degeneration, unspecified, H Age-related choroidal atrophy, right H Age-related choroidal atrophy, left H Age-related choroidal atrophy, H Diffuse secondary atrophy of choroid, right H Diffuse secondary atrophy of choroid, left H Diffuse secondary atrophy of choroid, H31.21 Choroideremia H31.29 Other hereditary choroidal dystrophy H Choroidal rupture, right H Choroidal rupture, left H Choroidal rupture, H Hemorrhagic choroidal detachment, right H Hemorrhagic choroidal detachment, left H Hemorrhagic choroidal detachment, H Serous choroidal detachment, right H Serous choroidal detachment, left H Serous choroidal detachment, H32 Chorioretinal disorders in diseases classified elsewhere H Unspecified retinoschisis, right H Unspecified retinoschisis, left H Unspecified retinoschisis, H Cyst of ora serrata, right H Cyst of ora serrata, left H Cyst of ora serrata, H Other retinoschisis and retinal cysts, right H Other retinoschisis and retinal cysts, left H Other retinoschisis and retinal cysts, H33.21 Serous retinal detachment, right H33.22 Serous retinal detachment, left H33.23 Serous retinal detachment, H34.01 Transient retinal artery occlusion, right H34.02 Transient retinal artery occlusion, left H34.03 Transient retinal artery occlusion, H34.11 Central retinal artery occlusion, right H34.12 Central retinal artery occlusion, left H34.13 Central retinal artery occlusion, H Retinal artery branch occlusion, right Printed on 1/29/2018. Page 13 of 24

14 ICD-10 Codes H Retinal artery branch occlusion, left H Retinal artery branch occlusion, H Central retinal vein occlusion, right, with macular edema H Central retinal vein occlusion, right, with retinal neovascularization H Central retinal vein occlusion, right, stable H Central retinal vein occlusion, left, with macular edema H Central retinal vein occlusion, left, with retinal neovascularization H Central retinal vein occlusion, left, stable H Central retinal vein occlusion,, with macular edema H Central retinal vein occlusion,, with retinal neovascularization H Central retinal vein occlusion,, stable H Venous engorgement, right H Venous engorgement, left H Venous engorgement, H Tributary (branch) retinal vein occlusion, right, with macular edema H Tributary (branch) retinal vein occlusion, right, with retinal neovascularization H Tributary (branch) retinal vein occlusion, right, stable H Tributary (branch) retinal vein occlusion, left, with macular edema H Tributary (branch) retinal vein occlusion, left, with retinal neovascularization H Tributary (branch) retinal vein occlusion, left, stable H Tributary (branch) retinal vein occlusion,, with macular edema H Tributary (branch) retinal vein occlusion,, with retinal neovascularization H Tributary (branch) retinal vein occlusion,, stable H34.9 Unspecified retinal vascular occlusion H Exudative retinopathy, right H Exudative retinopathy, left H Exudative retinopathy, H Hypertensive retinopathy, right H Hypertensive retinopathy, left H Hypertensive retinopathy, H Retinal micro-aneurysms, unspecified, right H Retinal micro-aneurysms, unspecified, left H Retinal micro-aneurysms, unspecified, H Retinal neovascularization, unspecified, right H Retinal neovascularization, unspecified, left H Retinal neovascularization, unspecified, H Retinal vasculitis, right H Retinal vasculitis, left H Retinal vasculitis, H Retinal telangiectasis, right H Retinal telangiectasis, left H Retinal telangiectasis, H35.09 Other intraretinal microvascular abnormalities H35.21 Other non-diabetic proliferative retinopathy, right H35.22 Other non-diabetic proliferative retinopathy, left H35.23 Other non-diabetic proliferative retinopathy, H Nonexudative age-related macular degeneration, right, early dry stage H Nonexudative age-related macular degeneration, right, intermediate dry stage H Nonexudative age-related macular degeneration, right, advanced atrophic without subfoveal involvement H Nonexudative age-related macular degeneration, right, advanced atrophic with subfoveal involvement H Nonexudative age-related macular degeneration, left, early dry stage H Nonexudative age-related macular degeneration, left, intermediate dry stage H Nonexudative age-related macular degeneration, left, advanced atrophic without subfoveal involvement H Nonexudative age-related macular degeneration, left, advanced atrophic with subfoveal involvement Printed on 1/29/2018. Page 14 of 24

15 ICD-10 Codes H Nonexudative age-related macular degeneration,, early dry stage H Nonexudative age-related macular degeneration,, intermediate dry stage H Nonexudative age-related macular degeneration,, advanced atrophic without subfoveal involvement H Nonexudative age-related macular degeneration,, advanced atrophic with subfoveal involvement H Exudative age-related macular degeneration, right, with active choroidal neovascularization H Exudative age-related macular degeneration, right, with inactive choroidal neovascularization H Exudative age-related macular degeneration, right, with inactive scar H Exudative age-related macular degeneration, left, with active choroidal neovascularization H Exudative age-related macular degeneration, left, with inactive choroidal neovascularization H Exudative age-related macular degeneration, left, with inactive scar H Exudative age-related macular degeneration,, with active choroidal neovascularization H Exudative age-related macular degeneration,, with inactive choroidal neovascularization H Exudative age-related macular degeneration,, with inactive scar H35.33 Angioid streaks of macula H Macular cyst, hole, or pseudohole, right H Macular cyst, hole, or pseudohole, left H Macular cyst, hole, or pseudohole, H Cystoid macular degeneration, right H Cystoid macular degeneration, left H Cystoid macular degeneration, H Drusen (degenerative) of macula, right H Drusen (degenerative) of macula, left H Drusen (degenerative) of macula, H Puckering of macula, right H Puckering of macula, left H Puckering of macula, H Toxic maculopathy, right H Toxic maculopathy, left H Toxic maculopathy, H35.52 Pigmentary retinal dystrophy H35.53 Other dystrophies primarily involving the sensory retina H35.54 Dystrophies primarily involving the retinal pigment epithelium H35.61 Retinal hemorrhage, right H35.62 Retinal hemorrhage, left H35.63 Retinal hemorrhage, H Central serous chorioretinopathy, right H Central serous chorioretinopathy, left H Central serous chorioretinopathy, H Serous detachment of retinal pigment epithelium, right H Serous detachment of retinal pigment epithelium, left H Serous detachment of retinal pigment epithelium, H Hemorrhagic detachment of retinal pigment epithelium, right H Hemorrhagic detachment of retinal pigment epithelium, left H Hemorrhagic detachment of retinal pigment epithelium, H35.81 Retinal edema H35.82 Retinal ischemia H43.11 Vitreous hemorrhage, right H43.12 Vitreous hemorrhage, left H43.13 Vitreous hemorrhage, H Vitreomacular adhesion, right H Vitreomacular adhesion, left H Vitreomacular adhesion, H43.89 Other disorders of vitreous body H43.9 Unspecified disorder of vitreous body H44.21 Degenerative myopia, right H44.22 Degenerative myopia, left Printed on 1/29/2018. Page 15 of 24

16 ICD-10 Codes H44.23 Degenerative myopia, H44.2A1 Degenerative myopia with choroidal neovascularization, right H44.2A2 Degenerative myopia with choroidal neovascularization, left H44.2A3 Degenerative myopia with choroidal neovascularization, H44.2B1 Degenerative myopia with macular hole, right H44.2B2 Degenerative myopia with macular hole, left H44.2B3 Degenerative myopia with macular hole, H44.2E1 Degenerative myopia with other maculopathy, right H44.2E2 Degenerative myopia with other maculopathy, left H44.2E3 Degenerative myopia with other maculopathy, H46.01 Optic papillitis, right H46.02 Optic papillitis, left H46.03 Optic papillitis, H Ischemic optic neuropathy, right H Ischemic optic neuropathy, left H Ischemic optic neuropathy, H47.10 Unspecified papilledema H Drusen of optic disc, right H Drusen of optic disc, left H Drusen of optic disc, H Pseudopapilledema of optic disc, right H Pseudopapilledema of optic disc, left H Pseudopapilledema of optic disc, H Other disorders of optic disc, right H Other disorders of optic disc, left H Other disorders of optic disc, H Cystoid macular edema following cataract surgery, right H Cystoid macular edema following cataract surgery, left H Cystoid macular edema following cataract surgery, M06.9 Rheumatoid arthritis, unspecified Q14.8 Other congenital malformations of posterior segment of Z Other long term (current) drug therapy Group 2 Paragraph: ICD-10 Codes For Indocyanine Green Angiography (92240) Group 2 Codes: ICD-10 Codes A18.53 Tuberculous chorioretinitis D31.31 Benign neoplasm of right choroid D31.32 Benign neoplasm of left choroid H Unspecified disseminated chorioretinal inflammation, right H Unspecified disseminated chorioretinal inflammation, left H Unspecified disseminated chorioretinal inflammation, H Disseminated chorioretinal inflammation of posterior pole, right H Disseminated chorioretinal inflammation of posterior pole, left H Disseminated chorioretinal inflammation of posterior pole, H Disseminated chorioretinal inflammation, peripheral right H Disseminated chorioretinal inflammation, peripheral, left H Disseminated chorioretinal inflammation, peripheral, H Disseminated chorioretinal inflammation, generalized, right H Disseminated chorioretinal inflammation, generalized, left H Disseminated chorioretinal inflammation, generalized, H31.8 Other specified disorders of choroid Printed on 1/29/2018. Page 16 of 24

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426)

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Local Coverage Determination (LCD): Ophthalmic Angiography (Fluorescein and Indocyanine Green) (L34426) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431)

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431) Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

2009 REIMBURSEMENT GUIDE, VISUCAM and VISUCAM NM/FA

2009 REIMBURSEMENT GUIDE, VISUCAM and VISUCAM NM/FA 2009 REIMBURSEMENT GUIDE FF 450 PLUS PRO NM, VISUCAM and VISUCAM NM/FA Zeiss Fundus Cameras INTRODUCTION The following guide provides an overview of billing and reimbursement for procedures performed with

More information

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431)

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431) Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmoscopy (L34017) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Ophthalmoscopy (L34017) Document Information Local Coverage Determination (LCD): Ophthalmoscopy (L34017) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Hospice - Neurological Conditions (L31537) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Hospice - Neurological Conditions (L31537) Document Information Local Coverage Determination (LCD): Hospice - Neurological Conditions (L31537) Contractor Information Contractor Name Palmetto GBA opens in new window LCD Information Document Information Contract Number

More information

What Is O.C.T. and Why Should I Give A Rip? OCT & Me How Optical Coherence Tomography Changed the Life of a Small Town Optometrist 5/19/2014

What Is O.C.T. and Why Should I Give A Rip? OCT & Me How Optical Coherence Tomography Changed the Life of a Small Town Optometrist 5/19/2014 OCT & Me How Optical Coherence Tomography Changed the Life of a Small Town Optometrist Email: myoder@wcoil.com Mark A. Yoder, O.D. 107 N. Main Street PO Box 123 Bluffton, OH 45817 @yoderod 115.02 Histoplasma

More information

Jurisdiction New Mexico. Retirement Date N/A

Jurisdiction New Mexico. Retirement Date N/A Local Coverage Determination (LCD): Chiropractic Services (L34816) Contractor Information Contractor Name Novitas Solutions, Inc. opens in new Contract Number 04212 Contract Type A and B MAC J - H LCD

More information

Local Coverage Determination (LCD): RAST Type Tests ( L30524 )

Local Coverage Determination (LCD): RAST Type Tests ( L30524 ) Page 2 of 6 Local Coverage Determination (LCD): RAST Type Tests ( L30524 ) Contractor Information Contractor Name Novitas Solutions, Inc. Contract Number 12502 Contract Type A and B MAC LCD Information

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A Local Coverage Determination (LCD): MolDX: GeneSight Assay for Refractory Depression (L36324) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Document Information Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Hospice Alzheimer's Disease & Related Disorders (L31539)

Contractor Information. LCD Information. Local Coverage Determination (LCD): Hospice Alzheimer's Disease & Related Disorders (L31539) Local Coverage Determination (LCD): Hospice Alzheimer's Disease & Related Disorders (L31539) Contractor Information Contractor Name Palmetto GBA opens in new window LCD Information Document Information

More information

Contractor Information

Contractor Information Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (L35038) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor

More information

PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q deletion analysis (DL36483)

PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q deletion analysis (DL36483) moldx: Chromosome 1p/19q deletion analysis (DL36483) Page 1 of 8 PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Chromosome 1p/19q deletion analysis (DL36483) Close Section Navigation

More information

and at the same patient encounter. Code has been deleted. For scanning computerized ophthalmic diagnostic imaging of optic nerve and retin

and at the same patient encounter. Code has been deleted. For scanning computerized ophthalmic diagnostic imaging of optic nerve and retin 92227: Remote imaging for detection of retinal disease (eg, retinopathy in a patient with diabetes) with analysis and report under physician supervision, unilateral or bilateral. For Medicare, bill only

More information

LCD Information Document Information LCD ID Number L30046

LCD Information Document Information LCD ID Number L30046 Local Coverage Determination (LCD): Pathology and Laboratory: B-type Natriuretic Peptide (BNP) Testing (L30046) LCD Information Document Information LCD ID Number L30046 LCD Title Pathology and Laboratory:

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Magnetic Resonance Angiography (L34424) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Magnetic Resonance Angiography (L34424) Document Information Local Coverage Determination (LCD): Magnetic Resonance Angiography (L34424) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

Local Coverage Determination for Hospice - Liver Disease (L31536)

Local Coverage Determination for Hospice - Liver Disease (L31536) Page 1 of 5 Centers for Medicare & Medicaid Services Print Message: If you are experiencing issues printing this page, then please click Return to Previous Page and select the 'Need a PDF?' button. You

More information

ICD-10-CM Are You Prepared? Part IV Posterior Segment

ICD-10-CM Are You Prepared? Part IV Posterior Segment ICD-10-CM Are You Prepared? Part IV Posterior Segment Rebecca H. Wartman OD April 2014 With contributions from Doug Morrow OD & Harvey Richman OD Overview This webinar will provide an introduction to ICD-10-CM

More information

MolDX: Chromosome 1p/19q deletion analysis

MolDX: Chromosome 1p/19q deletion analysis MolDX: Chromosome 1p/19q deletion analysis CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the current

More information

Local Coverage Article for Chiropractic Services (A47798) Contractor Information. Article Information. Contractor Name. Contractor Numbers

Local Coverage Article for Chiropractic Services (A47798) Contractor Information. Article Information. Contractor Name. Contractor Numbers Local Coverage Article for Chiropractic Services (A47798) Print Contractor Information Contractor Name Novitas Solutions, Inc. Contractor Numbers 12501, 12502, 12101, 12102, 12201, 12202, 12301, 12302,

More information

Contractor Information

Contractor Information Local Coverage Determination (LCD): Visual Fields (L34615) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Wisconsin

More information

Local Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice)

Local Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice) Local Coverage Determination (LCD) for Chiropractic Services (L34816) (Posted for Notice) Print Contractor Information Contractor Name Novitas Solutions, Inc. Contractor Numbers 04911, 07101, 07102, 07201,

More information

Contractor Number Oversight Region Region IV

Contractor Number Oversight Region Region IV Local Coverage Determination (LCD) for Hospice - Renal Care (L31538) Contractor Information Contractor Name Palmetto GBA opens in new window Contractor Number 11004 Contractor Type HHH MAC LCD Information

More information

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy

MolDX: HLA-DQB1*06:02 Testing for Narcolepsy MolDX: HLA-DQB1*06:02 Testing for Narcolepsy CGS Administrators, LLC Jump to Section... Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the

More information

LCD L B-type Natriuretic Peptide (BNP) Assays

LCD L B-type Natriuretic Peptide (BNP) Assays LCD L30559 - B-type Natriuretic Peptide (BNP) Assays Contractor Information Contractor Name: Novitas Solutions, Inc. Contractor Number(s): 12501, 12502, 12101, 12102, 12201, 12202, 12301, 12302, 12401,

More information

Local Coverage Determination for Hospice The Adult Failure To Thrive Syndrome (L31541)

Local Coverage Determination for Hospice The Adult Failure To Thrive Syndrome (L31541) Page 1 of 5 Centers for Medicare & Medicaid Services Print Message: If you are experiencing issues printing this page, then please click Return to Previous Page and select the 'Need a PDF?' button. You

More information

Local Coverage Determination for Hospice Alzheimer's Disease &Related Disorders (L31539)

Local Coverage Determination for Hospice Alzheimer's Disease &Related Disorders (L31539) Page 1 of 6 Centers for Medicare & Medicaid Services Print Message: If you are experiencing issues printing this page, then please click Return to Previous Page and select the 'Need a PDF?' button. You

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Texas. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Texas. Retirement Date N/A Local Coverage Determination (LCD): Chiropractic Services (L35424) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS

OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS UnitedHealthcare Commercial Medical Benefit Drug Policy OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS Policy Number: PHA020 Effective Date: September 1, 2018 Table of Contents

More information

Jurisdiction Georgia. Retirement Date N/A

Jurisdiction Georgia. Retirement Date N/A If you wish to save the PDF, please ensure that you change the file extension to.pdf (from.ashx). Local Coverage Determination (LCD): Surgery: Injections of the Spinal Canal (L32112) Contractor Information

More information

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors Ophthalmologic Policy UnitedHealthcare Commercial Drug Policy Vascular Endothelial Growth Factor (VEGF) Inhibitors Policy Number: 2016D0042H Effective Date: October 1, 2016 Table of Contents Page INSTRUCTIONS

More information

Posterior Segment Update

Posterior Segment Update Posterior Segment Update Featured Speaker: Dr. Kyle Cheatham, FAAO, DIP ABO DISCLOSURE STATEMENT We have no direct financial or proprietary interest in any companies, products or services mentioned in

More information

Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute

Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates

More information

Local Coverage Determination for Colorectal Cancer Screening (L29796)

Local Coverage Determination for Colorectal Cancer Screening (L29796) Page 1 of 15 Home Medicare Medicaid CHIP About CMS Regulations & Guidance Research, Statistics, Data & Systems Outreach & E People with Medicare & Medicaid Questions Careers Newsroom Contact CMS Acronyms

More information

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L33751)

Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L33751) Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L33751) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

More information

Implementing New & Revised ICD-10 Codes

Implementing New & Revised ICD-10 Codes Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates cgreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates

More information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Document Information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Document Information FUTURE Local Coverage Determination (LCD): Trigger Point Injections (L35010) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective

More information

PART 1: GENERAL RETINAL ANATOMY

PART 1: GENERAL RETINAL ANATOMY PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is

More information

Central venous occlusion

Central venous occlusion Central venous occlusion Central venous occlusion (right eye) There are dark haemorrhages at the macula and all over the retina. Choroidal haemangioma A choroidal haemangioma has salmon pink colour. There

More information

Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891)

Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891) Local Coverage Determination (LCD): Speech-Language Pathology (SLP) Services: Dysphagia; Includes VitalStim Therapy (L34891) Links in PDF documents are not guaranteed to work. To follow a web link, please

More information

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint Retina Coding and Reimbursement 101 William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan Genentech Regeneron

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome Quality ID #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

ICD-10-CM Are you Prepared? Disclaimers for Presentation. Disclaimers for Presentation 5/13/2014. What is ICD-10-CM/PCS

ICD-10-CM Are you Prepared? Disclaimers for Presentation. Disclaimers for Presentation 5/13/2014. What is ICD-10-CM/PCS AOA Third Party Center Coding Experts Are you Prepared? Rebecca H. Wartman O.D. Optometry s Meeting 2014 With contributions from Doug Morrow O.D. & Harvey Richman O.D. Rebecca H. Wartman, O.D Douglas C.

More information

Note: This is an outcome measure and can be calculated solely using registry data.

Note: This is an outcome measure and can be calculated solely using registry data. Measure #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery -- National Quality Strategy Domain: Effective Clinical Care DESCRIPTION: Percentage of patients

More information

Eylea (aflibercept) Document Number: IC-0026

Eylea (aflibercept) Document Number: IC-0026 Eylea (aflibercept) Document Number: IC-0026 Last Review Date: 3/1/2018 Date of Origin: 02/07/2013 Dates Reviewed: 03/07/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 04/2015,

More information

Contractor Information

Contractor Information Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (L35038) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor

More information

Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC B. LCD ID Number: L34834 Status: A-Approved

Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC B. LCD ID Number: L34834 Status: A-Approved LCD for Blood Glucose Monitoring in a Skilled Nursing Facility (SNF) (L34834) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12502 Contractor Type: MAC B LCD ID Number: L34834 Status: A-Approved

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. PROPOSED/DRAFT Local Coverage Determination (LCD): Virtual Colonoscopy (CT Colonography) (DL33452) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please

More information

Reimbursement Guidelines for Scanning Computerized Ophthalmic Diagnostic Imaging. Prepared for

Reimbursement Guidelines for Scanning Computerized Ophthalmic Diagnostic Imaging. Prepared for Reimbursement Guidelines for Scanning Computerized Ophthalmic Diagnostic Imaging Prepared for April 2010 Reimbursement Guidelines for Scanning Computerized Ophthalmic Diagnostic Imaging by Corcoran Consulting

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A Local Coverage Determination (LCD): MolDX: ConfirmMDx Epigenetic Molecular Assay (L36328) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor

More information

04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts

04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts Documentation Do s and Don ts In The Retina Practice William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan

More information

b. To facilitate the management decision of a patient with an equivocal stress test.

b. To facilitate the management decision of a patient with an equivocal stress test. National Imaging Associates, Inc. Clinical guidelines EBCT HEART CT & HEART CT CONGENITAL CCTA CPT4 Codes: 75571 EBCT 75572, 75573 Heart CT & Heart CT Congenital 75574 - CCTA LCD ID Number: L33559 J K

More information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Pain Management (L35033) Document Information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Pain Management (L35033) Document Information FUTURE Local Coverage Determination (LCD): Pain Management (L35033) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective Date.

More information

Rare Presentation of Ocular Toxoplasmosis

Rare Presentation of Ocular Toxoplasmosis Case Report Rare Presentation of Ocular Toxoplasmosis Rakhshandeh Alipanahi MD From Department of Ophthalmology, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. Correspondence:

More information

OCT Angiography in Primary Eye Care

OCT Angiography in Primary Eye Care OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

ZEISS AngioPlex OCT Angiography. Clinical Case Reports Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy

More information

The College of Optometrists - Learning outcomes for the Professional Certificate in Medical Retina

The College of Optometrists - Learning outcomes for the Professional Certificate in Medical Retina Learning outcomes for the Professional Certificate in Medical Retina, incorporating diabetic retinopathy screening and age related macular degeneration The professional certificate is a prerequisite to

More information

CMS Limitations Guide - Radiology Services

CMS Limitations Guide - Radiology Services CMS Limitations Guide - Radiology Services Starting October 1, 2015, CMS will update their existing medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitations

More information

Dr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding

Dr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding Dr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding Experts 92000 Codes Special Ophthalmological Services Describe

More information

FUTURE DRAFT Local Coverage Determination (LCD) for Corneal Pachymetry (DL32410)

FUTURE DRAFT Local Coverage Determination (LCD) for Corneal Pachymetry (DL32410) FUTURE DRAFT Local Coverage Determination (LCD) for Corneal Pachymetry (DL32410) Please note: This is a Draft policy. Draft LCDs are works in progress that are available on the Medicare Coverage Database

More information

Dr/ Marwa Abdellah EOS /16/2018. Dr/ Marwa Abdellah EOS When do you ask Fluorescein angiography for optic disc diseases???

Dr/ Marwa Abdellah EOS /16/2018. Dr/ Marwa Abdellah EOS When do you ask Fluorescein angiography for optic disc diseases??? When do you ask Fluorescein angiography for optic disc diseases??? 1 NORMAL OPTIC DISC The normal optic disc on fluorescein angiography is fluorescent due to filling of vessels arising from the posterior

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A Local Coverage Determination (LCD): Bone Mass Measurement (L36460) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

Moncef Khairallah, MD

Moncef Khairallah, MD Moncef Khairallah, MD Department of Ophthalmology, Fattouma Bourguiba University Hospital Faculty of Medicine, University of Monastir Monastir, Tunisia INTRODUCTION IU: anatomic form of uveitis involving

More information

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127

Clinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127 Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Electrical Stimulation Device Used for Cancer Treatment

Electrical Stimulation Device Used for Cancer Treatment Electrical Stimulation Device Used for Cancer Treatment OPTUNE (NOVOTTF 100A SYSTEM) For any item to be covered by The Health Plan, it must: 1. Be eligible for a defined Medicare or The Health Plan benefit

More information

Measure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery

Measure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery Measure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery 2012 PHYSICIAN QUALITY REPORTING OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: Percentage

More information

NOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by

NOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by NOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by the American Medical Association. You are forbidden

More information

Disease-Specific Fluorescein Angiography

Disease-Specific Fluorescein Angiography Ruth E. Picchiottino, CRA Disease-Specific Fluorescein Angiography 15 Disease-Specific Fluorescein Angiography Recommendations for tailoring retinal fluorescein angiography to diabetic retinopathy, macular

More information

The Human Eye. Cornea Iris. Pupil. Lens. Retina

The Human Eye. Cornea Iris. Pupil. Lens. Retina The Retina Thin layer of light-sensitive tissue at the back of the eye (the film of the camera). Light rays are focused on the retina then transmitted to the brain. The macula is the very small area in

More information

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy Integrated Healthcare Services and Criteria Document: Reference #: PC/V001 Page: 1 of 9 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services,

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY

More information

Cardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function.

Cardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function. National Imaging Associates, Inc. Clinical guidelines CARDIOVASCULAR NUCLEAR MEDICINE -MYOCARDIAL PERFUSION IMAGING -MUGA CPT4 Codes: Refer to pages 6-9 LCD ID Number: L33960 J 15 = KY, OH Responsible

More information

Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015

Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 So What Parts of the Eye Retina are Affected by VHL Neural tissue

More information

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517 Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

MEDICAL POLICY I. POLICY POLICY TITLE VISUAL FIELD TESTING POLICY NUMBER MP

MEDICAL POLICY I. POLICY POLICY TITLE VISUAL FIELD TESTING POLICY NUMBER MP Original Issue Date (Created): 8/9/2002 Most Recent Review Date (Revised): 11/28/2017 Effective Date: 10/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS

More information

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES

PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES A. GENERAL PROVISIONS 1. Eye Examination Benefits Optometric benefits are services defined in Section 23 of the Medical and Health Care Services Regulations,

More information

measure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control

More information

Subject: Electroretinography

Subject: Electroretinography 01-92000-28 Original Effective Date: 05/15/15 Reviewed: 03/22/18 Revised: 01/01/19 Subject: Electroretinography THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS,

More information

Ophthalmology Coding: Raise Your Eye-Q. Nancy Clark, CPC, COC, CPB, CPMA, CPC-I

Ophthalmology Coding: Raise Your Eye-Q. Nancy Clark, CPC, COC, CPB, CPMA, CPC-I Ophthalmology Coding: Raise Your Eye-Q Nancy Clark, CPC, COC, CPB, CPMA, CPC-I 1 Disclaimer The information in this presentation was current at the time the presentation was compiled. Always consult CPT,

More information

Diabetic Retinopathy

Diabetic Retinopathy Diabetic Retinopathy Diabetes can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus, formerly known as insulin-dependent diabetes mellitus, and non-insulin diabetes mellitus, respectively.

More information

Clinical Policy: Verteporfin (Visudyne) Reference Number: CP.PHAR.187

Clinical Policy: Verteporfin (Visudyne) Reference Number: CP.PHAR.187 Clinical Policy: (Visudyne) Reference Number: CP.PHAR.187 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

UVEITIS. Dr. Yılmaz ÖZYAZGAN

UVEITIS. Dr. Yılmaz ÖZYAZGAN UVEITIS Dr. Yılmaz ÖZYAZGAN UVEITIS DEFINITION BY STRICT DEFINITION, UVEITIS IS AN INFLAMMATION OF UVEAL TRACT. BUT IN PRACTICAL, IT IS GENERALLY NOT RESTRICTED TO THE UVEA AND INVOLVES OTHER ADJACENT

More information

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Lumbar Epidural Injections (L33836)

Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Lumbar Epidural Injections (L33836) FUTURE Local Coverage Determination (LCD): Lumbar Epidural Injections (L33836) Please note: Future Effective Date. Contractor Information Contractor Name Noridian Healthcare Solutions, LLC opens in new

More information

A Patient s Guide to Diabetic Retinopathy

A Patient s Guide to Diabetic Retinopathy Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes

More information

evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography

evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography Dr. Mahmoud Alaa Abouhusssein, FRCO Lecturer of ophthalmology, Alexandria university Dr. Amir Ramadan Gomaa, MD

More information

Contractor Number 03201

Contractor Number 03201 Local Coverage Article for Bone Mass Measurements Coverage - 2012 CPT Updates (A51577) Contractor Information Contractor Name Noridian Administrative Services, LLC opens in new window Contractor Number

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Cardiac Rehabilitation (L34412) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Cardiac Rehabilitation (L34412) Document Information Local Coverage Determination (LCD): Cardiac Rehabilitation (L34412) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

Local Coverage Determination (LCD) for Endoscopic Treatment of GERD (L28256)

Local Coverage Determination (LCD) for Endoscopic Treatment of GERD (L28256) Search Home Medicare Medicaid CHIP About CMS Regulations & Guidance Research, Statistics, Data & Systems Outreach & Education People with Medicare & Medicaid Questions Careers Newsroom Contact CMS Acronyms

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Chiropractic Services (L37387) Document Information

Contractor Information. LCD Information. Local Coverage Determination (LCD): Chiropractic Services (L37387) Document Information Local Coverage Determination (LCD): Chiropractic Services (L37387) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor

More information

11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES

11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES MACULAR MALADIES: TYPICAL & ATYPICAL CASES Dawn Pewitt, OD, FAAO Triad Eye Institute, Grove, OK Dpewitt@triadeye.com Disclosure Statement: No financial disclosures COPE 51218-PS Please silence all mobile

More information

Professional CGM Reimbursement Guide

Professional CGM Reimbursement Guide Professional CGM Reimbursement Guide 2015 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................

More information

The legally binding text is the original French version

The legally binding text is the original French version The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 12 September 2007 INFRACYANINE 25 mg/10 ml, powder and solvent for solution for injection 25 mg vial with one 10 ml

More information

Clinically Significant Macular Edema (CSME)

Clinically Significant Macular Edema (CSME) Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2

More information

Contractor Information

Contractor Information Local Coverage Determination (LCD): Category III Codes (L35490) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name

More information

Technicians & Nurses Program

Technicians & Nurses Program ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans ICD-10 Implementation: Tips and Pearls for Technicians Financial Disclosure The instructor acknowledges a financial

More information